NCT06034002 2026-04-17
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
Incyte Corporation
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
Hangzhou GluBio Pharmaceutical Co., Ltd.